Answers are grounded in this paper and cite their sources.
Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.
No takes yet. Share an insight, caveat, or question.
Alhaidar et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: